# A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

> **NCT03447249** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 385 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-659/TEZ/IVA
- **DRUG:** IVA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03447249
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-07
- **Primary completion:** 2019-02-05
- **Final completion:** 2019-02-05
- **Target enrollment:** 385 (ACTUAL)
- **Last updated:** 2020-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03447249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03447249, "A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03447249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*